Exabis Library
Welcome to the e-CCO Library!
P403: Treatment naïve newly diagnosed patients with Crohn's disease have microbial dysbiosis correlated with disease activity and faecal calprotectin—results from a prospective inception cohort
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P404 Prolonged steroid exposure prior to admission is associated with increased likelihood of rescue therapy and colectomy in acute severe ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P404: Development of anti-drug antibodies among those treated with adalimumab and ABP 501 and its impact on serum drug concentration in randomised controlled studies
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P404: Healthcare utilization and expenditures for patients with Ulcerative Colitis on advanced therapies in Germany
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P404: Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remission
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P404: Real-life experience with golimumab in ulcerative colitis patients according to prior anti-TNF use
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P404: Stopping 5-aminosalicylates in Crohn’s disease patients starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P404: Underrepresentation of minorities and lack of race reporting in ulcerative colitis drug development clinical trials
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P404: Vaccinations and immunization status in Paediatric inflammatory bowel disease: data from the VIP IBD study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P405 Comparison of long-term outcomes of infliximab vs. adalimumab in 1488 biologic-naive Korean patients with Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P405: 5-ASA prescription trends over time in inflammatory bowel disease 1996 to 2015–A UK population-based study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P405: Development and validation of a rapid immunoassay for monitoring of ustekinumab concentrations in Inflammatory Bowel Disease patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P405: Infliximab trough level measured during treatment induction may be predictive of the loss of response to Infliximab during treatment maintenance in inflammatory bowel disease patients: a longitudinal observational retrospective study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P405: Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P405: Primary non-response and loss-of-response to first-line biological therapies are more common in patients with Ulcerative Colitis than Crohn’s Disease – preliminary results from the Danish IBD Biobank Project
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P405: Sustainability of biologic therapies is less in UC than CD patients independent of prior biologic experience
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P405: Toxicity of thiopurines in patients with inflammatory bowel disease: inventory and predictive factors
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P406 Adherence, acceptability and serum trough concentration of adalimumab autoinjector in quiescent patients with inflammatory bowel diseases
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P406: A retrospective analysis of the efficacy of vedolizumab on extra-intestinal manifestations in patients with inflammatory bowel disease across five European countries
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P406: AlphaE+ cells have increased expression of inflammatory markers and are correlated in the ileum and colon
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM